This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Biotech ETFs Hovering Around a 52-Week: Here's Why
by Sanghamitra Saha
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
Biotech ETFs Bounce Back in 2025: Here's Why
by Sanghamitra Saha
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
4 Best-Performing Sector ETFs of June
by Sweta Killa
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Biotech ETFs Stage Solid Comeback at the Start of 2024
by Sweta Killa
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
5 Least-Hurt Biotech ETFs of the Last Week
by Sanghamitra Saha
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
2 Sector ETFs Hovering Around a 52-Week High
by Sanghamitra Saha
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
5 Best Areas of Q3 of 2022 & Their Top ETFs
by Sanghamitra Saha
These ETF areas won in the third quarter of 2022.
Biotech & Crypto -- Best ETF Areas of Last Week
by Sanghamitra Saha
Biotech and cryptocurrency -- two ETF areas outperformed last week.
Biotech Wins Last Week: 5 Best ETFs
by Sweta Killa
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO
by Zacks Equity Research
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.